Along with beneficial renal outcomes and reduced kidney insults in T2DM patients, SGLT2is have also galvanized their position as a potential treatment candidate for diabetic cardiomyopathy and other cardiac disorders owing to their direct SGLT2-independent cardiac effects, thus encouraging further applications of SGLT2is in other metabolic co-morbidities like non-alcoholic liver steatohepatitis (NASH), with or without diabetes/obesity. Here, SLC5A2 is linked to diabetic cardiomyopathy.